

2013-2014

Support from Pharmaceutical Companies and Device Manufacturers and American Heart Association Total Corporate Support

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association's finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau's Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials. Contributions from corporations account for just 20.1 percent.

Financial support from corporations helps the association's programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association's corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the entire American Heart Association, including National Center, its Affiliates and local offices. It represents approximately 20.1 percent of the AHA's \$784,707,034 in total revenue (2013-2014 audited financial statements).

Support that the American Heart Association receives from pharmaceutical companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 2.1 percent of the association's total revenue (2013-2014 audited financial statements). The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed during fiscal year 2013-2014, noting that, in some cases, the funds will be received in future years.



NOTE: The Pie Chart above shows income committed in fiscal year 2013-2014 to the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers and the amount of total corporate support committed to AHA association-wide, compared to all sources of revenue.

Listed below in the middle column is cash received by the American Heart Association from pharmaceutical companies, device manufacturers and health insurance providers during fiscal year 2013-2014.

In addition, in the right column, we have listed revenue that was committed to the American Heart Association during fiscal year 2013-2014, but will actually be received in future years. An example is a multi-year sponsorship of an American Heart Association program or campaign.

FY 2013-2014 Contributed income and advertising revenue contributed to AHA¹ from pharmaceutical, medical device companies and health insurance providers		
Corporation	Total Cash Received During FY 2013-2014 on Prior and Current Year Commitments²	Current Year FY 2013-2014 Commitments Receivable in the Future
Abbott Vascular	-	55,000
Affinity Health Plan, Inc	140,000	-
Amarin	165,000	-
Amgen	891,060	1,685,000
Arthrex	85,000	-
Astellas	50,000	-
AstraZeneca	620,000	415,000
Bayer	180,000	100,000
BMS/Pfizer	1,360,000	-
Boehringer Ingelheim Pharmaceuticals	945,953	84,000
Boston Scientific	400,000	-
CardioDX	15,000	25,000
Cigna	120,000	-
CIPLA	48,000	-
Covidien	1,150,000	-
CPR Working Group	43,750	131,250
Daiichi Sankyo	1,527,500	-
Edward Lifesciences LLC	400,000	-
Eli Lilly	75,000	-
Florida Blue	130,000	-
Forest Laboratories	45,000	-
GE Healthcare	5,000	-
Genentech	992,390	-
GlaxoSmithKlein	25,000	-
Jabil	125,000	-
Janssen	570,000	225,000
Kaiser Permanente National Community Benefit Fund at the East Bay Community Foundation	250,000	2,750,000
KLA-Tencor Corporation	75,000	-
LipoScience	50,000	-

Medtronic	60,000	290,000
Merck	400,700	210,000
Novartis Pharmaceuticals	600,000	414,854
Patriot National Insurance Group	100,000	-
Penn Mutual	75,000	-
Pfizer	3,280,875	-
Philips	15,000	333,500
Physio-Control	-	10,000
Sanofi	-	215,000
Siemens	-	75,000
Takeda Pharmaceutical Company	50,000	203,990
The Medicines Company	15,000	-
Vivus	50,000	-
Western Health Advantage	100,000	-
Zoll Medical	15,000	-
Totals	\$15,245,228	\$7,222,594

Note: (1) Reflects all corporate contributions to National Center and 10 highest corporate contributions to each Affiliate.

Note (2) Column includes cash received on commitments from contracts and conferences. This was recorded as revenue in FY 2010-2011, FY 2011-12, FY 2012-13 and FY 2013-14.